Individuals with complete filaggrin deficiency may have an increased risk of squamous cell carcinoma

British Journal of Dermatology

Volumn 170, Issue 6, 2014, Pages 1380-1381

  Kaae, J ^a   Szecsi, P B ^a   Meldgaard, M ^a   Espersen, M L M ^a   Stender, S ^a   Johansen, J D ^a   Bandier, J ^a   Thyssen, J P ^a   Menne T ^a   Nielsen, S L ^a   Hogdall E ^a   Balslev, E ^a   Skov, L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FILAGGRIN; GENOMIC DNA; HEMATOXYLIN; PROTEINASE K; INTERMEDIATE FILAMENT PROTEIN;

ATOPIC DERMATITIS; BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER RISK; CHROMATOPHORE; DIGESTION; FILAGGRIN DEFICIENCY; HETEROZYGOTE; HUMAN; LETTER; LOSS OF FUNCTION MUTATION; MALIGNANT TRANSFORMATION; NON MELANOMA SKIN CANCER; PATHOLOGIST; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PUNCH BIOPSY; SAMPLE SIZE; SQUAMOUS CELL CARCINOMA; STRATUM CORNEUM; SUN EXPOSURE; TISSUE SECTION; ULTRAVIOLET RADIATION; VITAMIN BLOOD LEVEL; ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; DEFICIENCY; GENETICS; MIDDLE AGED; MUTATION; RISK FACTOR; SKIN NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MIDDLE AGED; MUTATION; RISK FACTORS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84903180308     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12911     Document Type: Letter

References (10)

1. Barresi C, Stremnitzer C, Mlitz V, et al,. Increased sensitivity of histidinemic mice to UVB radiation suggests a crucial role of endogenous urocanic acid in photoprotection. J Invest Dermatol 2011; 131: 188-94.
2. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al,. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
3. Jensen AO, Svaerke C, Kormendine FD, et al,. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977-2006). Am J Clin Dermatol 2012; 13: 29-36.
4. Berg ND, Husemoen LL, Thuesen BH, et al,. Interaction between filaggrin null mutations and tobacco smoking in relation to asthma. J Allergy Clin Immunol 2012; 129: 374-80.
5. Jorgensen T, Borch-Johnsen K, Thomsen TF, et al,. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 2003; 10: 377-86.
6. Meldgaard M, Szecsi PB, Carlsen BC, et al,. A novel multiplex analysis of filaggrin polymorphisms: a universally applicable method for genotyping. Clin Chim Acta 2012; 413: 1488-92.
7. Carlsen BC, Meldgaard M, Johansen JD, et al,. Filaggrin compound heterozygous patients carry mutations in trans position. Exp Dermatol 2013; 22: 572-5.
8. Elias PM, Williams ML,. Comment on 'Does a history of eczema predict a future basal cell carcinoma?' J Invest Dermatol 2013; 133: 1676-7.
9. Thyssen JP, Thuesen B, Huth C, et al,. Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxyvitamin D concentrations. J Allergy Clin Immunol 2012; 130: 1204-7.
10. Kaae J, Thyssen JP, Johansen JD, et al,. Filaggrin gene mutations and risk of basal cell carcinoma. Br J Dermatol 2013; 169: 1162-4.